Transforming growth factor alpha (TGFa) is a principal molecule in the normal and neoplastic development of the mammary gland. Binding of TGFa to the epidermal growth factor receptor (EGFR), activates the EGFRs' endogenous tyrosine kinase activity and stimulates growth of the epithelium in the virgin and pregnant mouse mammary gland. TGFa expression can be detected in breast cancer cells in vivo and in vitro and overexpression can elicit partial transformation or immortalized human and rodent mammary epithelial cells. Despite evidence implicating TGFa in the development of mammary neoplasia, the actual mechanism of TGFa-induced transformation is unclear. Transgenic mouse models targeting heterologus TGFa to the mammary gland have established TGFa overexpression can induce hyperproliferation, hyperplasia and occasional carcinoma. These transgenic studies demonstrated a facilitating, proliferative role for TGFa in the development of neoplasia and implicated several oncogenes that can cooperate with TGFa to transform the mammary epithelium. From studies of EGFR signaling pathways, inhibitory and modulating agents such as anti-EGFR antibodies and speci®c kinases inhibitors have been used to block the action of this pathway and prevent the development of TGFa-induced neoplasia and tumor formation. Studies in Stat5a knockout mice have established that the JAK2/Stat5a pathway can facilitate the survival of the mammary epithelium and can impact the progression of TGFa-mandated mammary tumorigenesis. Together these experiments indicate that TGFa and the EGFR signaling pathway are potentially amenable to therapies for treatment of human breast disease.
Introduction
Development and progression of breast cancer, like many other types of human cancer, is dependent on the progressive corruption and alteration of normal signaling pathways. Signaling mechanisms that transmit growth signals are a predominant target for carcinogenic and oncogenic alterations as they often confer a growth advantage to the pre-neoplastic cell. One of the primary growth factor receptors involved in normal and neoplastic development of the mammary gland is the EGFR and its extended family of related receptors and peptide ligands (Table 1) . EGFR and the ligand TGFa, have expression levels altered in the development of cancer in numerous issues. The related family of ligands that bind to these receptors; EGF, heregulin, amphiregulin, and cripto also display alterations in their expression and activity within the pre-neoplastic and transformed cell (for a review see (Dickson and Lippman, 1995; Gullick et al., 1999; Schroeder and Lee, 1997) ). Despite the well characterized role of the EGFR and TGFa in normal mammary growth signaling, in transformation of mammary epithelial cells in vitro and in vivo and their elevated expression in some breast cancers, the speci®c alterations of the EGFR signaling mechanism that lead to TGFa-initiated neoplasia are poorly understood. In an attempt to elucidate these alterations, several transgenic mouse models have been generated to explore the role of TGFa and EGFR in mammary neoplasia. This review will focus on TGFa and its role in transformation of the mammary gland. In addition, it will examine those studies that have attempted to identify the mechanisms of TGFa action in the mammary gland and those molecules that are capable of cooperatively interacting with TGFa to promote tumorigenesis.
TGFa and EGFR expression coincides with normal proliferation in vivo
TGFa is structurally and functionally similar to EGF; the peptides share a 42% identity and can elicit the same biological eects in cultured mammary epithelial cells and explants (Daniel and Silberstein, 1985; Salomon et al., 1987; Vonderhaar, 1987) . TGFa is often co-expressed with the EGFR and binding to the receptor activates the EGFRs' endogenous tyrosine kinase activity. Mammary epithelial cell lines can be stimulated to proliferate by TGFa (Smith et al., 1989; Zajchowski and Sager, 1991) and it can act as an autocrine growth factor in normal and immortalized human mammary epithelial cells. TGFa autocrine and proliferative activity can be blocked in these cells by an anti-EGFR antibody (Bates et al., 1990; Kenney et al., 1993) .
In normal mammary gland development, TGFa and EGF transcripts can be detected in the ductal and lobuloalveolar stages. The virgin mouse mammary gland expresses TGFa in the proliferative cap cells and the stromal ®broblasts around the neck of the terminal endbud, whereas EGF expression is localized *Correspondence: RC Humphreys Oncogene (2000) 19, 1085 ± 1091 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc to the luminal ductal epithelium (Snedeker et al., 1991) . In the absence of ovarian steroids, exogenous TGFa and EGF can stimulate ductal growth of the mouse mammary epithelium suggesting that they can act independently of secondary signals (Snedeker et al., 1991) . EGF and TGFa mRNA is present in pregnant and lactating rat and human mammary glands and increases 2 ± 3-fold over virgin levels at pregnancy (Liscia et al., 1990) . The EGFR is required for ductal development (Wiesen et al., 1999) and can be detected in both the stromal and epithelial components of the virgin mammary gland (Coleman et al., 1988) . In the pregnant gland, a rapid increase is observed during midpregnancy precisely at the time of extensive cellular proliferation (Edery et al., 1985) . After pregnancy, the levels of EGFR decrease signi®cantly. The coincident expression of TGFa and its receptor with the proliferative phases of mammary epithelial growth and TGFas' direct mitogenic eect on epithelium in vitro and in vivo con®rms the functional role for this signaling dyad in the development and proliferation of the mammary epithelium.
TGFa expression is associated with human breast cancer
TGFa is expressed and mitotically active in numerous breast cancer cell lines and has been directly implicated as a modulator of transformation in vivo (Borellini and Oka, 1989; Daniel and Silberstein, 1985; de Jong et al., 1998a; Salomon et al., 1984; Valverius et al., 1989) . In fact, the discovery of TGFa was based on its ability to transform retrovirally-infected cultured ®broblasts (Todaro et al., 1980; de Larco and Todaro, 1978) . Expression of TGFa has been identi®ed in pleural eusions from normal mammary gland (Arteaga et al., 1988) , in invasive ductal carcinoma (Pilichowska et al., 1997) and correlates with increased neo-angiogensis (de Jong et al., 1998b) in breast tumors. Carcinomas of the breast that have higher level expression of TGFa also express high levels of EGFR, implicating a functional role for the TGFa/EGFR autocrine loop in tumors (Umekita et al., 1992) . The correlation between levels of EGFR expression and neoplastic transformation in vivo is controversial (Gullick and Srinivasan, 1998) . Robertson and colleagues demonstrated that 40 ± 60% of neoplasias examined in one study displayed normal levels of EGFR expression (Robertson et al., 1996) . Only a small proportion of breast cancers has elevated levels of EGFR (Slamon et al., 1987) , or ampli®cation of EGFR (Peters and Wol, 1983) . This data implies that alterations in EGFR ligands may be more in¯uential on the activity of the EGFR than changes in the levels of receptor expression itself. Alternatively, the formation of heterodimers between EGFR and the other erbB family members may play a role in eecting dierential activities in tumorigenesis of the breast.
TGFa can modulate cellular transformation in breast cancer cell lines. In the immortalized human breast cancer cell line, MCF-7, TGFa transfected cells that expressed EGFR were stimulated to grow in a colony forming assay . In a parallel study with fully transformed MCF-7 cells that lacked EGFR, TGFa transfection did not eect a positive growth advantage (Clarke et al., 1989) . Overexpression of TGFa in the immortalized mouse mammary cell line, NOG-8, generated anchorage independent growth but colonies failed to form tumors in nude mice (Shankar et al., 1989) . Therefore, expression of TGFa is associated with the ability to stimulate growth, while overexpression is allied with partial transformation in vitro and correlated with appearance of carcinomas in vivo.
TGFa transgenic mouse models of breast cancer
Mouse models have been developed to study the role of TGFa in the transformation and development of the mammary gland. Several promoters have been utilized to target TGFa both non-speci®cally and speci®cally to the mammary gland. These mouse models have established the importance of TGFa in the early stages of neoplastic development of the mammary gland.
Initial studies demonstrating the neoplasia-promoting activity of TGFa were described in mice expressing human TGFa under the control of the zinc-inducible metallothionein (MT) promoter (Jhappan et al., 1990) . Despite the fact that expression of the transgene was low in the mammary gland and was generally not inducible, these mice displayed increased cellular proliferation and delayed epithelial penetration of the stromal fatpad during ductal development. In a second parallel study, using the MT promoter directing the expression of rat TGFa, Sandgren and colleagues noticed that mice that had passed through multiple pregnancies developed hyperplastic nodules and dysplasia of the mammary epithelium (Sandgren et al., 1990) . Only one mouse developed a secretory adenocarcinoma. These studies demonstrated that there was an association between the in vivo expression of TGFa and the development of mammary hyperplasia.
A study directing TGFa expression speci®cally to the mammary gland with the mouse mammary tumor virus (MMTV) promoter demonstrated unequivocally the growth and neoplasia promoting activity of TGFa (Matsui et al., 1990) . Precocious alveolar development, hyperproliferation and hyperplasias were apparent in the mature virgin mouse. The alveolar hyperplasia was present in glands from mature virgin mice, but not in immature virgin mice, suggesting a requirement for secondary inputs from systemic hormones for any TGFa-dependent hyperplasia to occur. Hyperplastic alveolar nodules and cysts were prominent in the multiparous animal and increased in hyperplastic and dysplastic character with the number of pregnancies. One multiparous mouse developed adenocarcinomas although none were metastatic. A second study was performed with the MMTV-TGFa mice that studied in greater detail the generation of hyperplasia and tumors (Halter et al., 1992) . At one year, 65% of multiparous and 45% of virgin mice displayed hyperplasia. By 16 months, 40% of the multiparous and 30% of the virgin mice and mice had generated tumors. These studies demonstrated that TGFa could stimulate the proliferation of the mammary epithelium and generate proliferative late pregnancy mammary gland phenotypes in early pregnant animals. In addition, the hyperplasia, dysplasia and frank carcinoma observed with this mouse model suggested that there was a multistage nature to the progression of TGFa-initiated transformation.
A more dramatic mammary phenotype was achieved by targeting rat TGFa exclusively to the mammary gland with the WAP-TGFa transgenic mouse (Sandgren et al., 1995) . This transgenic model achieved high level TGFa expression during pregnancy and lactation and displayed similar proliferative mammary gland phenotypes as described in the MT and MMTV transgenic models but with an increased incidence and decreased latency of tumors. In addition, the process of involution, in which the gland absorbs and reorganizes a signi®cant portion of its epithelial structure, was delayed in these mice as it was in the original MT mice (Sandgren et al., 1990) . Latency of tumor appearance was decreased in comparison to the MMTV-TGFa model, but still required several rounds of pregnancy for initial tumor development. A majority of the tumors were well-dierentiated glandular adenomas or carcinomas (53%) and ®broadenomas (35%) and retained the glandular characteristics of late pregnant mammary epithelium. The appearance of multiple types of tumor and the retention of normal glandular morphologies suggested that these dierent types were stages of TGFa-dependent tumor progression. Interestingly, the levels of cyclinD1 were elevated in the WAP-TGFa transgenic glands. The targeted overexpression of this cell cycle regulatory molecule is known to eect mammary transformation (Wang et al., 1994) and is in a chromosomal region frequently rearranged in human breast cancer Gillett et al., 1994 Gillett et al., , 1996 Gillett et al., , 1999 . This indicates that cyclinD1 may be a cooperative factor in the development of TGFa induced mammary carcinogenesis. The delay in involution was suggested as a mechanism for promoting transformation of the mammary gland as it provided an expanded population of proliferative epithelial cells that could be predisposed to transformation. This seminal paper demonstrated TGFa could transform the mammary Figure 1 Involution is enhanced in the absence of Stat5a. Hemotoxylin and eosin staining of inguinal mammary glands from Stat5a null non-transgenic (NTGKO), wildtype (WT), Stat5a null TGFa transgenic (KOTG) and TGFa transgenic (TG) mice at 18 days of pregnancy (p18/a ± d), days 1 (i1/e ± h), 3 (i3/i ± l) and 7 (i7/m ± p) of involution. Samples were collected from mice in or immediately after their ®rst pregnancy. Compare epithelial condensation at day 3 and 7 of involution in the wildtype (1-j) versus the KOTG (1-k) and TG (1-l). Magni®cation is de®ned by the bar in a =200 mm. Reproduced with permission (Humphreys and Hennighausen, 1999) epithelium and suggested a possible mechanism for neoplastic development. The observation that TGFa could cause a delay in involution was supported by results from a separate study with MT-TGFa mice . An increase in DNA synthesis in lactation was accompanied by a signi®cant decrease in apoptotic cells after 2 days of involution. Involution was also aected in a mouse model utilizing WAPTGFa and the Stat5a knockout mouse (Humphreys and Hennighausen, 1999) . In the absence of Stat5a, apoptosis levels rose in the mammary gland during pregnancy and involution. This increase in apoptosis enhanced involution of the WAP-TGFa gland ( Figure  1 ) and increased the latency of WAP-TGFa-induced tumors. This result demonstrated the WAP-TGFainduced delay in involution and tumor formation, could be abrogated by a downstream signaling molecule that regulates cell death in the mammary epithelium.
Subsequent studies examined the role that oncogenes may play in acting cooperatively with TGFa to promote mammary transformation. The oncogene cmyc is overexpressed in 25 ± 30% of breast cancer (Bonilla et al., 1988; Callahan and Campbell, 1989; Mariani-Costantini et al., 1988 Morse et al., 1988) and in rodent mammary epithelial cell lines transfected with myc, TGFa could cooperate to support a transformed phenotype (Telang et al., 1990) . Mice that overexpressed both c-myc and TGFa in the mammary gland had an increased tumor incidence and decreased tumor latency when compared to c-myc transgenics (Amundadottir et al., 1995) . A second paper utilizing the same bitransgenic mice demonstrated that the synergism between these two proteins was due to a cooperative growth stimulus and inhibition of c-myc-induced apoptosis by TGFa (Amundadottir et al., 1996) . Apoptotic tumors were present exclusively in mice that expressed only c-myc. In cell lines derived from these tumors, exogenous TGFa could inhibit apoptosis. These data again implicated TGFa as a survival factor in the mammary epithelium. Interestingly, tumor cells from the mammary glands of these bitransgenic mice could only become apoptotic when exposed to a speci®c inhibitor of the EGFR kinase pathway. This result suggested that an intact TGFa/ EGFR autocrine loop was required to mediate the survival eects of TGFa.
Interaction between TGFa and the proto-oncogene neu was examined in bitransgenic mice expressing both Figure 2 Model of the TGFa/EGF signal transduction pathway and EGFR signaling inhibitors that aect EGFR-mediated transformation. EGF and TGFa binding to the EGFR stimulate the activation of the endogenous receptor tyrosine kinase. The membrane-bound EGFR kinase activates one of several intracellular signal transduction pathways including the protein kinase A, Ras/Raf/MAPK, c-src and Jak/Stat pathways. Direct or indirect phosphorylation and activation of one or more of the Stat proteins, 1, 3, 5a, and 5b can be achieved through several of these mechanisms. The activating kinase, attributes of the targeted Stat and phosphorylated residue can elicit distinct functional consequences for the cell. Multiple intercellular pathways can lead to activation of the Stats and other nuclear factors like myc and cyclinD1. Each of these pathways can be blocked by speci®c inhibitors (shown in red Italics). The proliferative stimulus provided by TGFa and EGF in cooperation with transforming oncogenes can lead to cellular transformation. Consequently, a clear understanding of the mechanisms involved and the use of multifocal inhibitors of signaling intermediaries is critical for eectual inhibition of EGFR signal transduction. Some alternative and intermediary intercellular signaling molecules have been omitted for clarity genes under the control of the MMTV promoter (Muller et al., 1996) . The neu proto-oncogene is a member of the EGFR family and although it does not bind to TGFa or EGF, it can form heterodimers with the EGFR and it is often found overexpressed and ampli®ed in human breast cancers (Slamon et al., 1987) . Tumor latency was decreased in the bitransgenic mice, compared to the TGFa and neu, monotransgenic lines. At 150 days 95% of the bitransgenic mice had mammary tumors vs 6% and 35% for the TGFa and neu mice, respectively. Bitransgenic tumors were multifocal whereas mono-transgenic lines generated focal tumors and contained activated neu. This paper suggested a novel mechanism for TGFa cooperativity involving the transactivation of neu through the EGFR. Treatment of MMTV-TGFa mice with the tumor promoter 7, 12 dimethyl benzanthracene demonstrated that TGFa could accelerate tumor formation and the authors suggested that TGFa could act as a tumor promoter (Coey et al., 1994) .
These studies on the mechanism of TGFa-mediated tumorigenesis and cooperativity in the mammary gland demonstrate that the overexpression of TGFa gives the preneoplastic mammary epithelium a proliferative advantage but in and of itself is not a transforming event. Secondary events, like the activation of proto-oncogenes, can signi®cantly increase the eciency with which TGFa can transform the mammary epithelium. Importantly, these studies support the theory that TGFa's in¯uence on the regulation of apoptosis in the mammary gland is a possible mechanism of promoting survival of the neoplastic cell.
Disruption of TGFa signaling and potential therapies for breast cancer
The EGFR is required for mammary gland ductal development (Wiesen et al., 1999; Xie et al., 1997) and, as described previously, is aberrantly expressed in 40% of human breast cancers and occasionally overexpressed in those tumors with poor prognosis. This receptor can interact with several distinct ligands (Table 1) and activates dierent intracellular and nuclear signaling pathways (Figure 2 ). Substrates for this type 1 receptor tyrosine kinase are numerous and demonstrate the in¯uence of EGFR on the regulation of cellular growth. Importantly, it is clear that this receptor plays a central role in the development and progression of human breast cancer. Therefore, insight into EGFR signal transduction and the mechanism of substrate selection and activation are critical to understanding the development of breast cancer. The EGFR and its interaction with TGFa has been and continues to be a target for potential anti-cancer therapies that aim to regulate its activity and signaling mechanisms.
A recent study demonstrated that inhibition of the signal from EGFR to its intracellular signaling molecules is critical in blocking tumor progression. Treatment of MMTV-TGFa transgenic mice with a farnesyl transferase inhibitor, which blocks Ras function, demonstrated a signi®cant regression of mammary tumors (Norgaard et al., 1999) . This inhibitory eect was ineectual after tumor acceleration from multipregnancy or after treatment with the carcinogen DMBA supporting the theory that that EGFR signaling is important in the initial stage of neoplastic development. The EGFR can activate the intracellular tyrosine kinases Jak1 and the transcription factors Stat1, 3 and 5b in response to growth signaling from EGF (Leonard and O'Shea, 1998) . Recent data has demonstrated that growth hormone activated Ras/Raf/MAPK pathway can directly activate the normally cytokine-activated pathway of Stat5a (Pircher et al., 1999) and EGF can phosphorylate Stat5a through c-src (Olayioye et al., 1999) . Stat5a, a prolactin-activated transcription factor, has an established role in the development and differentiation of the lactation-competent mammary gland (Liu et al., 1987) but is also associated with signaling in tumor cells (Hayakawa et al., 1998; Richer et al., 1998; Yu et al., 1997; Zhang et al., 1996) . Stat5a-null mice interbred with WAP-TGFa transgenic mice revealed inhibition of TGFa-dependent MAPK activation and TGFa-dependent apoptosis inhibition after deletion of Stat5a. The increase in apoptosis permitted a more complete epithelial regression to occur at involution (Figure 1) . A more complete regression deleted a signi®cant number of potentially neoplastic cells and this impacted WAP-TGFa driven tumorigenesis. Stat5a null/WAP TGFa transgenic mice had an increase in tumor latency when compared to the WAP-TGFa transgenic. These mice displayed an increase in apoptosis before and during involution. These data suggested Stat5a was acting as a survival factor for the mammary epithelium by blocking the onset of apoptosis. Theoretically, the absence of Stat5a permitted apoptosis to occur and thereby diminished the pool of potential neoplastic cells that could become transformed (Humphreys and Hennighausen, 1999) .
A novel mechanism of inhibition of TGFa activity was demonstrated recently in human mammary epithelial cells with an anti-metalloproteinase. Metalloproteinases are extracellular enzymes that cleave components of the extracellular matrix including the EGFR ligands; TGFa and EGF. This cleavage event releases them from the cell surface rendering the growth factor into an active form. These metalloproteinase inhibitors prevented TGFa release from the cell surface, blocked cell migration and decreased proliferation. Additionally, the metalloproteinase inhibitors reduced the growth of EGF-dependent tumor cell lines and could synergize with anti-EGFR antibodies (Dong et al., 1999) .
Therapies for inhibiting the action of EGFR and indirectly the action of TGFa, to block tumorigenesis are being explored. Current research into the action of molecules that may have a role in regulating the TGFa signaling pathway like EGFR-speci®c monoclonal antibodies (Ciardiello et al., 1999) , protein kinase A inhibitors, a combination of antibodies and chemotheraputic agents (Bianco et al., 1997; Ciardiello et al., 1996; Ciardiello and Tortora, 1998) , antiestrogens like taxol, raloxifen, alone or in combination with antibodies like the humanized monoclonal antibody to neu; Herceptin (Brenner and Adams, 1999; Hanna et al., 1999; Robertson, 1998; Ross and Fletcher, 1998) , provide some promising results for future treatment of breast cancer.
Conclusions
Transgenic mouse model studies have given us insight into possible mechanism of TGFa-initiated breast cancer. Overexpression of TGFa may be an early prognostic factor in the initiation of this disease and in cooperation with secondary transforming events can lead to carcinoma. Importantly, the role of TGFa in the inhibition of apoptosis during normal development could lead to a critical understanding of the role this growth factor plays in normal and neoplastic development in the mammary gland. This growth factor pathway appears to be able to promote growth in the initial phase of neoplastic transformation although it lacks the dominating transformation ability observed with some of the other EGFR-related mouse models of mammary gland disease like MMTV/erb-2 (Guy et al., 1992; Siegel et al., 1999) . In combination with an understanding of TGFa signaling mechanisms, inhibitory agents, which act on the receptor-ligand interaction or on the intracellular kinases stimulated by the EGFR, could lead to practical and ecacious treatment regimens for this disease.
